Tosufloxacin tosylate hydrate
Based on 2 publication(s) in Google Scholar
Tosufloxacin tosylate hydrate (A-61827) is an orally active fluoroquinolone antibiotic. Tosufloxacin shows a broad spectrum of antibacterial activity against gram-positive and gram-negative bacteria.
For research use only. We do not sell to patients.
- Purity: 99.95%
- CAS No.: 1400591-39-0
- Formula: C26H25F3N4O7S
- Molecular Weight:594.56
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Tosufloxacin tosylate hydrate
MoreAll Antibiotic Isoforms
More
Biological Activity
|
Quinolone |
Tosufloxacin tosylate hydrate (T-3262) (0.05-3.13 μg/mL; 18 h) shows antibacterial activities against S. aureus, Staphylococcus epidermidis, streptococci, enterococci, Bacteroides fragilis, Clostridium difficile, and Clostridium perfringens[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:S. aureus, Staphylococcus epidermidis, streptococci, enterococci, Bacteroides fragilis, Clostridium difficile, and Clostridium perfringens
-
Concentration:0.05-3.13 μg/mL
-
Incubation Time:18 hours
-
Result:Showed MIC90s (MICs for 90% of the isolates tested) ranging from 0.05 to 1.56 μg/mL for S. aureus, Staphylococcus epidermidis, streptococci, and enterococci.
Showed MIC90s of 1.56, 3.13, and 0.20 μg/mL for Bacteroides fragilis, Clostridium difficile, and Clostridium perfringens, respectively.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Slc:ICR mice infected with S. aureus[2]
-
Dosage:1.27-2.15 mg/kg
-
Administration:Oral gavage; 1.27-2.15 mg/kg; once
-
Result:Showed 50% effective dose (ED50) of 1.62 mg/kg (body weight) at 7 days after infection.
Showed MIC value of 0.0125 μg/mL.
-
Animal Model:Male Slc:ICR mice infected with E. coli[2]
-
Dosage:0.16-0.30 mg/kg
-
Administration:Oral gavage; 0.16-0.30 mg/kg; once
-
Result:Showed 50% effective dose (ED50) of 0.22 mg/kg (body weight) at 7 days after infection.
Showed MIC value of 0.0125 μg/mL.
-
Animal Model:Male Slc:ICR mice infected with P. aeruginosa[2]
-
Dosage:7.66-13.39 mg/kg
-
Administration:Oral gavage; 7.66-13.39 mg/kg; once
-
Result:Showed 50% effective dose (ED50) of 10.13 mg/kg (body weight) at 7 days after infection.
Showed MIC value of 0.78 μg/mL.
Chemical Information
-
CAS No. 1400591-39-0
-
Appearance Solid
-
Molecular Weight 594.56
-
Formula C26H25F3N4O7S
-
Color White to off-white
-
SMILES
CC1=CC=C(S(=O)(O)=O)C=C1.O=C(C2=CN(C3=CC=C(F)C=C3F)C4=C(C=C(F)C(N5CC(N)CC5)=N4)C2=O)O.O
-
Synonyms
A-61827 tosylate hydrate; T-3262
-
Structure Classification
-
Initial Source
Salmonella enteritidis
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
PLoS Negl Trop Dis
Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti. [Abstract]2019 Aug 20;13(8):e0007681. PMID: 31430351 -
Curr Microbiol
Repurposing Sitafloxacin, Prulifloxacin, Tosufloxacin, and Sisomicin as Antimicrobials Against Biofilm and Persister Cells of Pseudomonas aeruginosa. [Abstract]2021 Dec 14;79(1):12. PMID: 34905092
Solvent & Solubility
DMSO : 12.5 mg/mL (21.02 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 1.25 mg/mL (2.10 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 1.25 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (2.10 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (283 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Chu DT, et al. Synthesis and biological properties of A-71497: a prodrug of tosufloxacin. Drugs Exp Clin Res. 1990;16(9):435-43. [Content Brief]
[2]. Fujimaki K, et al. In vitro and in vivo antibacterial activities of T-3262, a new fluoroquinolone. Antimicrob Agents Chemother. 1988 Jun;32(6):827-33. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.6819 mL | 8.4096 mL | 16.8192 mL | 42.0479 mL |
| 5 mM | 0.3364 mL | 1.6819 mL | 3.3638 mL | 8.4096 mL | |
| 10 mM | 0.1682 mL | 0.8410 mL | 1.6819 mL | 4.2048 mL | |
| 15 mM | 0.1121 mL | 0.5606 mL | 1.1213 mL | 2.8032 mL | |
| 20 mM | 0.0841 mL | 0.4205 mL | 0.8410 mL | 2.1024 mL |
Tosufloxacin tosylate hydrate Related Classifications
HY-B1802A Related Classifications
Powered by Bioz
- Tosufloxacin tosylate
- 1400591-39-0
- A-61827 tosylate
- T-3262
- T3262
- T 3262
- T-3262
- Bacterial
- Antibiotic
- antibacterial activity
- gram-positive bacteria
- gram-negative bacteria
- S. aureus
- Staphylococcus epidermidis
- streptococci
- enterococci
- Bacteroides fragilis
- Clostridium difficile
- Clostridium perfringens
- Inhibitor
- inhibitor
- inhibit